Estudio farmacocinético | 03 DIC 19

Ciprofloxacina en niños con infección urinaria complicada

Documentación de la farmacocinética sérica y urinaria de ciprofloxacina en niños con infección urinaria complicada
Autor/a: K. Meesters, R. Michelet, R. Mauel y colaboradores Fuente: Antimicrob Agents Chemother 62:e00517-18 Results of a Multicenter Population Pharmacokinetic Study of Ciprofloxacin in Children with Complicated Urinary Tract Infection
INDICE:  1. Texto principal | 2. Referencias bibliográficas
Referencias bibliográficas

Referencias

1. Shaikh N, Morone NE, Bost JE, Farrell MH. 2008. Prevalence of urinary tract infection in childhood. Pediatr Infect Dis J 27:302–308. https://doi.org/10.1097/INF.0b013e31815e4122.

2. Montini G, Tullus K, Hewitt I. 2011. Febrile urinary tract infections in children. N Engl J Med 365:239–250. https://doi.org/10.1056/NEJMra1007755.

3. Keren R, Shaikh N, Pohl H, Gravens-Mueller L, Ivanova A, Zaoutis L, Patel M, De Berardinis R, Parker A, Bhatnagar S, Haralam MA, Pope M, Kearney D, Sprague B, Barrera R, Viteri B, Egigueron M, Shah N, Hoberman A. 2015. Risk factors for recurrent urinary tract infection and renal scarring. Pediatrics 136:e13– e21. https://doi.org/10.1542/peds.2015-0409.

4. Abraham MB, Larkins N, Choong CS, Shetty VB. 2017. Transient pseudohypoaldosteronism in infancy secondary to urinary tract infection. J Paediatr Child Health 53:458–463. https://doi.org/10.1111/jpc.13481.

5. Mattoo TK, Chesney RW, Greenfield SP, Hoberman A, Keren R, Mathews R, Gravens-Mueller L, Ivanova A, Carpenter MA, Moxey-Mims M, Majd M, Ziessman HA. 2016. Renal scarring in the randomized intervention for children with vesicoureteral reflux (RIVUR) trial. Clin J Am Soc Nephrol 11:54–61. https://doi.org/10.2215/CJN.05210515.

6. Brandström P, Nevéus T, Sixt R, Stokland E, Jodal U, Hansson S. 2010. The Swedish Reflux Trial in Children. IV. Renal damage. J Urol 184:292–297. https://doi.org/10.1016/j.juro.2010.01.060.

7. Shaikh N, Craig JC, Rovers MM, Da Dalt L, Gardikis S, Hoberman A, Montini G, Rodrigo C, Taskinen S, Tuerlinckx D, Shope T. 2014. Identification of children and adolescents at risk for renal scarring after a first urinary tract infection: a meta-analysis with individual patient data. JAMA Pediatr 168:893–900. https://doi.org/10.1001/jamapediatrics.2014.637.

8. Strohmeier Y, Hodson EM, Willis NS, Webster AC, Craig JC. 2014. Antibiotics for acute pyelonephritis in children. Cochrane Database Syst Rev 7:CD003772. https://doi.org/10.1002/14651858.CD003772.pub4.

9. European Medicines Agency. EMA label guideline ciprofloxacin. Scientific conclusions and grounds for summaries of product characteristics, labelling and package leaflet for ciprofloxacin. European Medicines Agency, London, United Kingdom.

10. US Food and Drug Administration. 2004. FDA label guideline ciprofloxacin, p 1–31. Labelling leaflet for ciprofloxacin. US Food and Drug Administration, Rockville, MD.

11. Gagliotti C, Nobilio L, Moro ML. 2007. Emergence of ciprofloxacin resistance in Escherichia coli isolates from outpatient urine samples. Clin Microbiol Infect 13:328 –331. https://doi.org/10.1111/j.1469-0691.2006.01615.x.

12. Guillot E, Sermet I, Ferroni A, Chhun S, Pons G, Zahar J-R, Jullien V. 2010. Suboptimal ciprofloxacin dosing as a potential cause of decreased Pseudomonas aeruginosa susceptibility in children with cystic fibrosis. Pharmacotherapy 30:1252–1258. https://doi.org/10.1592/phco.30.12.1252.

13. Drlica K, Malik M, Kerns RJ, Zhao X. 2008. Quinolone-mediated bacterial death. Antimicrob Agents Chemother 52:385–392. https://doi.org/10.1128/AAC.01617-06.

14. Förster C, Kociok K, Shakibaei M, Merker HJ, Stahlmann R. 1996. Quinolone-induced cartilage lesions are not reversible in rats. Arch Toxicol 70:474–481. https://doi.org/10.1007/s002040050301.

15. Yoshida K, Yabe K, Nishida S, Yamamoto N, Ohshima C, Sekiguchi M, Yamada K, Furuhama K. 1998. Pharmacokinetic disposition and arthropathic potential of oral ofloxacin in dogs. J Vet Pharmacol Ther 21: 128–132. https://doi.org/10.1046/j.1365-2885.1998.00114.x.

16. Adefurin A, Sammons H, Jacqz-Aigrain E, Choonara I. 2011. Ciprofloxacin safety in paediatrics: a systematic review. Arch Dis Child 96:874–880. https://doi.org/10.1136/adc.2010.208843.

17. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. 2003. Developmental pharmacology—drug disposition, action, and therapy in infants and children. N Engl J Med 349:1157–1167. https://doi.org/10.1056/NEJMra035092.

 

Comentarios

Para ver los comentarios de sus colegas o para expresar su opinión debe ingresar con su cuenta de IntraMed.

CONTENIDOS RELACIONADOS
AAIP RNBD
Términos y condiciones de uso | Política de privacidad | Todos los derechos reservados | Copyright 1997-2024